Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue (Details Textual)

Note 3 - Revenue (Details Textual) $ / shares in Units, $ in Thousands					1 Months Ended		3 Months Ended				6 Months Ended	9 Months Ended		12 Months Ended
	May 19, 2021 USD ($)	Apr. 24, 2021 USD ($)	Mar. 24, 2021 USD ($) $ / shares shares	Feb. 08, 2018 USD ($)	Sep. 30, 2023 USD ($)	Jan. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2017	Jan. 01, 2019 USD ($)	May 02, 2017 USD ($)
Contract with Customer, Liability, Revenue Recognized							$ 17,100					$ 38,700
Contract with Customer, Liability, Current					$ 994		994				$ 994	994		$ 20,824
Increase (Decrease) in Contract with Customer, Liability							0					0
Amendment of the Second Seagen Amendment [Member]
Revenue from Contract with Customer, Excluding Assessed Tax					9,000
Genentech [Member]
Number Of Initial Research Programs	2
Contract with Customer, Liability, Revenue Recognized								$ 12,500
Revenue from Contract with Customer, Collaboration Fee On Additional Program	$ 10,000
Number Of Optional Additional Research Programs	2
Seattle Genetics Inc. [Member]
Number of Performance Obligations				3
Amended Collaboration Agreement, Resale of Stock, Period (Day)			60 days
Seattle Genetics Inc. [Member] \| Private Placement [Member]
Contract with Customer, Liability, Total			$ 3,300
Sale of Stock, Number of Shares Issued in Transaction (in shares) \| shares			3,706,174
Sale of Stock, Consideration Received on Transaction			$ 13,000
Sale of Stock, Price Per Share (in dollars per share) \| $ / shares			$ 3.51
Sale of Stock, Fair Value, Price Per Share (in dollars per share) \| $ / shares			$ 2.61
Seattle Genetics Inc. [Member] \| License and Collaboration Agreement [Member]
Number of Research Programs			3	3
Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)				12 months
Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)				90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)				180 days
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)				90 days
Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)				90 days
Number Of Licenses				3
Number Of Swap Options				2
Number of Performance Obligations				6
Revenue, Remaining Performance Obligation, Amount					1,000		1,000				1,000	1,000
Seattle Genetics Inc. [Member] \| Other Arrangement [Member]
Number of Research Programs				2
Seattle Genetics Inc. [Member] \| Up-front Payment Arrangement [Member]
Contract with Customer, Liability, Total				$ 1,200,000
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned				$ 4,900
Seattle Genetics Inc. [Member] \| Platform Technology License [Member]
Number of Performance Obligations				3
Number of Target Programs				3
Seattle Genetics Inc. [Member] \| Antibody Target Swap [Member]
Number of Performance Obligations				2
Seattle Genetics Inc. [Member] \| Governance Committee Participation [Member]
Number of Performance Obligations				1
Seattle Genetics Inc. [Member] \| Collaborative Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax						$ 5,000								5,000
Contract with Customer, Liability, Current					1,000		1,000				1,000	1,000
Astra Zeneca A B [Member]
Capitalized Contract Cost, Net, Total					100		100				100	100
Capitalized Contract Cost, Amortization									$ 200			300	$ 300
Astra Zeneca A B [Member] \| Accounting Standards Update 2014-09 [Member]
Capitalized Contract Cost, Net, Total																	$ 1,600
Capitalized Contract Cost, Gross																$ 1,100
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member]
Contract with Customer, Liability, Revenue Recognized											4,000			$ 9,700
Contract with Customer, Liability, Current					3,500		3,500				3,500	3,500
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member] \| Maximum [Member]
Number of Collaboration Products																	4
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member] \| Minimum [Member]
Number of Collaboration Products																	2
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
Contract with Customer, Liability, Revenue Recognized										$ 4,900
Number of Programs															4
Number of Novel Proteins															1
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| License and Collaboration Agreement [Member]
Contract with Customer, Liability, Current					$ 4,700		$ 4,700				$ 4,700	$ 4,700
Number of Programs															5
License [Member] \| Genentech [Member]
Contract with Customer, Liability, Total	$ 20,000
License [Member] \| B P Assets X I I Inc [Member] \| Exclusive Product License Agreement [Member]
Contract with Customer, Liability, Total		$ 10,000
Revenue from Contract with Customer, Contribution Towards Manufacturing Activities		$ 4,000
License [Member] \| Seattle Genetics Inc. [Member] \| Up-front Payment Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				$ 30,000